Pliant Therapeutics Inc (PLRX)

$11.8

-0.17

(-1.42%)

Market is closed - opens 7 PM, 17 Jun 2024

Insights on Pliant Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 248.0K → 4.83M (in $), with an average increase of 94.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -41.10M → -46.95M (in $), with an average decrease of 14.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 75.4% return, outperforming this stock by 125.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 237.0% return, outperforming this stock by 299.3%

Performance

  • $11.67
    $12.03
    $11.80
    downward going graph

    1.1%

    Downside

    Day's Volatility :2.99%

    Upside

    1.91%

    downward going graph
  • $10.60
    $24.05
    $11.80
    downward going graph

    10.17%

    Downside

    52 Weeks Volatility :55.93%

    Upside

    50.94%

    downward going graph

Returns

PeriodPliant Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-19.18%
0.4%
0.0%
6 Months
-28.35%
8.7%
0.0%
1 Year
-46.99%
10.3%
0.0%
3 Years
-61.15%
17.0%
-23.8%

Highlights

Market Capitalization
736.2M
Book Value
$7.25
Earnings Per Share (EPS)
-2.86
Wall Street Target Price
41.08
Profit Margin
0.0%
Operating Margin TTM
-78404.03%
Return On Assets TTM
-21.71%
Return On Equity TTM
-34.17%
Revenue TTM
248.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
9.7M
EBITDA
-192.5M
Diluted Eps TTM
-2.86
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.4
EPS Estimate Next Year
-3.71
EPS Estimate Current Quarter
-0.77
EPS Estimate Next Quarter
-0.81

Analyst Recommendation

Buy
    95%Buy
    5%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Pliant Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
19
19
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 248.14%

Current $11.80
Target $41.08

Technicals Summary

Sell

Neutral

Buy

Pliant Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pliant Therapeutics Inc
Pliant Therapeutics Inc
-24.41%
-28.35%
-46.99%
-61.15%
-44.6%
Moderna, Inc.
Moderna, Inc.
5.54%
63.93%
8.78%
-29.22%
787.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.08%
21.82%
32.37%
97.97%
233.31%
Novo Nordisk A/s
Novo Nordisk A/s
7.11%
43.97%
76.7%
240.79%
458.71%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
9.1%
18.8%
38.18%
156.4%
176.63%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pliant Therapeutics Inc
Pliant Therapeutics Inc
NA
NA
NA
-3.4
-0.34
-0.22
NA
7.25
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.71
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.32
30.32
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.73
49.73
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.07
31.07
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pliant Therapeutics Inc
Pliant Therapeutics Inc
Buy
$736.2M
-44.6%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$55.7B
787.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$113.1B
233.31%
30.32
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$634.9B
458.71%
49.73
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$123.6B
176.63%
31.07
39.46%

Institutional Holdings

  • Deep Track Capital, LP

    9.53%
  • BlackRock Inc

    7.72%
  • T. Rowe Price Associates, Inc.

    6.56%
  • FMR Inc

    6.54%
  • First Light Asset Management, LLC

    5.86%
  • Vanguard Group Inc

    5.77%

Company Information

pliant therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. by harnessing the therapeutic potential of integrin biology and tgf-β modulation, pliant aims to prevent or even reverse fibrosis to address the needs of many patients. the company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. pliant’s co-founders include world-renowned researchers from university of california, san francisco (ucsf), who bring broad experience in fibrosis biology and small molecule chemistry. together, the pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.

Organization
Pliant Therapeutics Inc
Employees
158
CEO
Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Industry
Health Technology

FAQs